Literature DB >> 20518636

Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection.

Mark Miller1, Lisa Bernard, Melissa Thompson, Daniel Grima, Jocelyne Pepin.   

Abstract

OBJECTIVE: To assess whether use of oral vancomycin for treatment during an outbreak of Clostridium difficile infection (CDI) was associated with increased rates of colonization with vancomycin-resistant enterococci (VRE).
DESIGN: A retrospective analysis of hospital databases.
SETTING: The Jewish General Hospital in Montreal, Quebec, Canada.
METHODS: We collected data regarding VRE colonization and CDI from November 1, 2000, through September 30, 2007, during which policies of preferential oral metronidazole or vancomycin treatment were implemented to control an outbreak of CDI. Four periods were considered: period 1, the preoutbreak period when metronidazole was used; period 2, the CDI outbreak period when metronidazole was used; period 3, the postoutbreak period when vancomycin was used; and period 4, the postoutbreak period when metronidazole was used.
RESULTS: A total of 2,412 cases of CDI and 425 cases of VRE colonization were identified. The rate of CDI increased significantly during period 2 and decreased to preoutbreak levels during period 3. The rate of VRE also increased during period 2 and decreased during the first 18 months of period 3. A clonal outbreak of cases of VRE (VanA) colonization was observed toward the end of period 3 and into period 4. Excluding the period of the clonal outbreak, there was a strong correlation between the number of cases of CDI and VRE colonization (r=0.736; P=.001) and a negative association between VRE colonization and vancomycin use (r=-0.765; P=.04).
CONCLUSIONS: Increased vancomycin use was not associated with an increase in VRE colonization over a 2-year period. Restriction of vancomycin use during CDI outbreaks because of the fear of increasing VRE colonization may not be warranted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20518636     DOI: 10.1086/653613

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  12 in total

1.  Reducing the risk of severe complications among patients with Clostridium difficile infection.

Authors:  Kamran Manek; Victoria Williams; Sandra Callery; Nick Daneman
Journal:  Can J Gastroenterol       Date:  2011-07       Impact factor: 3.522

2.  Clostridium Difficile Colitis in Trauma Patients - a Global Step by Step Review.

Authors:  Silviu Morteanu; Georgiana Chirt; Mircea Beuran
Journal:  Maedica (Buchar)       Date:  2015-06

3.  In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.

Authors:  Diane M Citron; Kerin L Tyrrell; C Vreni Merriam; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2011-12-19       Impact factor: 5.191

Review 4.  [Clostridium difficile infections in geriatric patients].

Authors:  R Simmerlein; A Basta; M Gosch
Journal:  Z Gerontol Geriatr       Date:  2016-10-26       Impact factor: 1.281

5.  Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.

Authors:  Alex Carignan; Sébastien Poulin; Philippe Martin; Annie-Claude Labbé; Louis Valiquette; Hamed Al-Bachari; Louis-Philippe Montpetit; Jacques Pépin
Journal:  Am J Gastroenterol       Date:  2016-09-13       Impact factor: 10.864

6.  When is an outbreak an outbreak? Using literature and discharge data to define Clostridioides difficile incidence changes referred to as outbreaks.

Authors:  C C Cohen; G Azhar; L Muggy
Journal:  J Hosp Infect       Date:  2020-03-20       Impact factor: 3.926

7.  Clostridium difficile-associated disease: adherence with current guidelines at a tertiary medical center.

Authors:  Bryan F Curtin; Yousef Zarbalian; Mark H Flasar; Erik von Rosenvinge
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

8.  Clostridium difficile--a moving target.

Authors:  Glenn S Tillotson; Joni Tillotson
Journal:  F1000 Med Rep       Date:  2011-03-01

9.  Impact of a Multimodal Antimicrobial Stewardship Program on Pseudomonas aeruginosa Susceptibility and Antimicrobial Use in the Intensive Care Unit Setting.

Authors:  Douglas Slain; Arif R Sarwari; Karen O Petros; Richard L McKnight; Renee B Sager; Charles J Mullett; Alison Wilson; John G Thomas; Kathryn Moffett; H Carlton Palmer; Harakh V Dedhia
Journal:  Crit Care Res Pract       Date:  2011-05-19

10.  Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization.

Authors:  Hee Kyoung Choi; Kye Hyung Kim; Sun Hee Lee; Su Jin Lee
Journal:  J Korean Med Sci       Date:  2011-06-20       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.